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Abstract
Background: Recent studies suggest that BRCA2 affects telomere maintenance. Interestingly, anti cancer
treatments that involve BRCA2 and telomerase individually are currently being explored. In the light of the above
recent studies their combinatorial targeting may be justified in the development of future treatments. In order to
investigate effects of BRCA2 that can be explored for this combinatorial targeting we focused on the analysis of
recombination rates at telomeres by monitoring T-SCEs (Telomere Sister Chromatid Exchanges).
Results: We observed a significant increase in T-SCE frequencies in four BRCA2 defective human cell lines thus
suggesting that BRCA2 suppresses recombination at telomeres. To test this hypothesis further we analyzed T-SCE
frequencies in a set of Chinese hamster cell lines with or without functional BRCA2. Our results indicate that
introduction of functional BRCA2 normalizes frequencies of T-SCEs thus supporting the notion that BRCA2
suppresses recombination at telomeres. Given that ALT (Alternative Lengthening of Telomeres) positive cells
maintain telomeres by recombination we investigated the effect of BRCA2 depletion in these cells. Our results
show that this depletion causes a dramatic reduction in T-SCE frequencies in ALT positive cells, but not in non-ALT
cells.
Conclusion: BRCA2 suppresses recombination at telomeres in cells that maintain them by conventional
mechanisms. Furthermore, BRCA2 depletion in ALT positive cells reduces high levels of T-SCEs normally found in
these cells. Our results could be potentially important for refining telomerase-based anti-cancer therapies.
Background
Telomeres are specialized nucleo-protein structures
involved in chromosome end protection. This protective
function requires an intricate coordination between the
mechanisms that maintain telomere structure and DNA
damage response mechanisms [1]. The importance of the
above coordination is highlighted by the fact that defects
in numerous DNA damage response proteins have acute
effects on telomere maintenance mechanisms. Selected
examples include proteins such as Ku and DNA-PKcs
involved in DNA double strand break (DSB) repair by
non-homologous end joining (NHEJ) [2], ATM, a protein
responsible for DNA damage signalling [3], MRN, a com-
plex consisting of MRE11, RAD50 and NBS proteins
responsible for DSB sensing [4] and ERCC1/XPF responsi-
ble for nucleotide excision repair (NER) [5].
Two recent studies revealed another DNA damage
response protein that affects telomere maintenance,
namely BRCA2 [6,7]. BRCA2 associates with telomeres
during S and G2 phases of the cell cycle and mediates
access of RAD51, a homologous recombination protein,
to telomeres [6]. A variety of telomere dysfunction phe-
notypes were observed when BRCA2 was defective
including telomere shortening, telomere fragility, TIFs
(Telomere dysfunction Induced Foci), and increased fre-
quencies of T-SCEs (Telomere Sister Chromatid
Exchanges) [6,7]. These findings are important because
BRCA2 is the first protein directly involved in human
cancer with a clear role in telomere maintenance. There-
fore, the findings may be relevant for both understanding
the role of BRCA2 in tumorigenesis and developing novel
therapeutic approaches. A number of interventions tar-
geting telomerase in cancer cells have been proposed and
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peutic approaches based on BRCA2 targeting are mainly
focused on exploring unusual sensitivity of BRCA2 defec-
tive tumors to Poly(ADP)ribose polymerase (PARP) inhi-
bitors [9,10]. Targeting telomerase and BRCA2 together
may be a potential future avenue for refining existing
therapeutic attempts (see below).
In this study we investigated effects of BRCA2 on
recombination rates at telomeres by analysing T-SCE fre-
quencies. T-SCEs represent a marker of recombination at
telomeres. Our results show that BRCA2 suppresses
recombination at telomeres in cells that maintain them by
conventional mechanisms. By contrast, ALT (Alternative
Lengthening of Telomeres) positive cells require BRCA2
as the frequencies of T-SCEs, one of the key ALT markers,
are dramatically reduced following BRCA2 knock-down.
Results and discussion
To investigate effects of BRCA2 dysfunction on recombi-
nation at telomeres we analysed T-SCE frequencies in a
primary fibroblast cell line, EUFA423, obtained from a
patient with biallelic mutations in BRCA2 (exons 15 and
27) leading to truncated proteins [11]. We used two pri-
mary fibroblast cell lines from normal individuals as
controls (Bebu and GM08399). In addition, we used two
primary fibroblast cell lines defective in Artemis (CJ179
and F01-240) [12], a NHEJ protein, to exclude the possibi-
lity that the effect of BRCA2 may be a consequence of a
defective DNA damage response and thus non-specific.
Our analysis revealed a statistically significant difference
(p < 0.05) in T-SCE frequencies between the EUFA423
cell line and all other cell lines (Figure 1A). Normal, con-
trol cell lines and Artemis defective cell lines showed < 1
T-SCE/cell (Figure 1A). In contrast, EUFA423 cells had ~
6 T-SCEs/cell (Figure 1A). Examples of T-SCEs observed
in the above cell lines are shown in Figure 1B.
We have also analyzed telomere length and telomere
function in the EUFA423 cell line and one control primary
cell line, Bebu. In line with recently published studies [6,7]
EUFA423 cells exhibited significantly shorter telomeres
and significantly elevated frequencies of telomeric fusions
relative to the control counterparts (Figure 1C &1D).
Furthermore, we analyzed frequencies of TIFs in both cell
lines. The EUFA423 cell line exhibited a ten-fold higher
frequencies of TIFs (49% cells TIF positive; n = 136; PD
20) in comparison with the control Bebu cells (5% cells
TIF positive; n = 106; PD 25). This difference was statisti-
cally significant (p < 0.05; t-test).
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Figure 1 Analysis of telomere maintenance in various cell lines. A. Frequencies of T-SCEs (event/metaphase) in 5 cell lines. A minimum of
30 metaphases/cell line were analyzed in two independent experiments. B. Examples of T-SCEs in a metaphase cell from the EUFA423 cell line.
Some of T-SCEs are indicated by arrows. C. Telomere length analysis by Q-FISH. TFI - telomere fluorescence intensity (arbitrary units). PD -
population doubling. D. Frequencies of chromosome fusions. Error bars represent SEM in A and D and SD in C.
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Page 2 of 7To test whether the elevated T-SCE frequency
observed in EUFA423 cells is specific to the BRCA2
defect we used additional BRCA2 defective cell lines.
These included: (i) Capan 1, the pancreatic carcinoma
cell line completely lacking one BRCA2 allele and con-
taining a truncation (6174delT) mutation in the other
allele leading to a truncated protein product [13] and (ii)
two lymphoblastoid cell lines, GM14622 and GM14170,
from patients with constitutive BRCA2 mutations (frame-
shift mutation 6503delTT in exon 11, leading to a trun-
cation at codon 2099 and a 1bp deletion at nucleotide
6174 in exon 11 resulting in a frameshift beginning at
codon 1982 and terminating at codon 2003) http://ccr.
coriell.org/Sections/BrowseCatalog/DiseaseDetail.aspx?
PgId=403&omim=BRC60018&coll=. The CO-FISH ana-
lysis revealed a sevenl-fold higher T-SCE frequency in
the Capan 1 cell line than in the control HeLa cell line
(Figure 2A). Similarly, T-SCE frequencies were several
times higher in the two BRCA2 defective lymphoblastiod
cell lines in comparison with the control cell line (Figure
2B). Therefore, elevated recombination rates at telomeres
observed in four different BRCA2 defective cell lines sug-
gest that BRCA2 suppresses recombination at telomeres.
This is in line with a recent study reporting elevated fre-
quencies of T-SCEs in BRCA2 heterozygous cell lines [7].
To further test the hypothesis that BRCA2 suppresses
recombination at telomeres we used a set of Chinese
hamster cell lines including a BRCA2 defective cell line,
V-C8, which shows two nonsense mutations in exons 15
and 16 of the Chinese hamster Brca2 gene resulting in
two truncated proteins [14], and two isogenic cell lines in
which the BRCA2 defect was corrected either as a result
of introducing a BAC with a functional copy of the mur-
ine Brca2 gene (V-C8+Brca2), or human chromosome 13
containing functional BRCA2 (V-C8+#13) [15]. The par-
ental V79B cell line with functional Brca2 w a su s e da sa
control cell line. As expected, V-C8 cells, showed several-
fold higher frequencies of T-SCEs relative to control V79
cells (Figure 2C). However, the correction of the BRCA2
defect resulted in significant reduction of T-SCE frequen-
cies (p < 0.05) (Figure 2C). In the case of the V-C8+#13
cell line the frequency of T-SCEs was the same as that
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Figure 2 Frequencies of T-SCEs in different sets of cell lines. A. Frequencies of T-SCE/cell in Capan-1 and HeLa cells. A minimum of 50
metaphases/cell line have been analyzed. Error bars represent SD. B. Frequenceis of T-SCEs in three lymphoblastoid cell lines: GM00893 (normal
control) GM14622 and GM14170 (cell lines established from BRCA2 carriers). A minimum of 50 metaphases/per cell line analyzed. Error bars
represent SEM. C. Frequencies of T-SCEs in a set of Chinese hamster cell lines: V79B (normal control); V-C8 (BRCA2 defective, see the text for
details), V-C8+#13 (the V-C8 cell line in which the BRCA2 defect was complemented by introducing human chromosome 13 containing the
BRCA2 gene) and V-C8+Brca2 (the V-C8 cell line transfetced with a BAC containing a copy of murine Brca2). A minimum of 50 cells/per cell line
analyzed. Error bars represent SEM.
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Page 3 of 7observed in the V79 cell line (Figure 2C). The V-C8
+Brca2 cell line showed somewhat higher frequency of
T-SCE relative to V79 cell line but still significantly lower
than in the V-C8 cell line (Figure 2C). These results sug-
gest that correction of the BRCA2 defect leads to normal-
ization of T-SCE frequencies, thus further supporting the
hypothesis that BRCA2 suppresses recombination at
telomeres.
The above findings are interesting from the perspective
of the ALT mechanisms for telomere maintenance. ALT
relies on recombination [16]a n dp r e v i o u ss t u d i e sh a v e
shown that BRCA2 associates with APBs (ALT-associated
Promyelocytic leukemia Bodies) [17] and that the knock-
down of FANCA and FANCD2 proteins, both involved in
the same pathway as FANCD1/BRCA2, causes reduction
of T-SCE frequencies in ALT positive cells [18]. Therefore,
we investigated the effect of BRCA2 depletion in ALT
positive cells. To this end we selected an ALT positive cell
line, U2OS, and determined T-SCE frequency, one of the
ALT markers [16], relative to the control non-ALT cell
line, HeLa. As expected U2OS cells showed approximately
10 fold higher frequencies of T-SCEs relative to HeLa cells
(results not shown). We then knocked-down BRCA2
expression in these two cell lines using siRNA oligonu-
cleotides specific for BRCA2. To verify the knock-down
we used quantitative RT-PCR and Western blot. The
RT-PCR results show that this procedure resulted in 70%-
85% BRCA2 knockdown 48h and 72h after transfection
(Figure 3A). A similar pattern was observed by Western
blot (Figure 3B).
Having verified the BRCA2 knockdown in the above
cell lines we investigated its effect on T-SCE frequencies.
In a pilot experiment we found that that the BRC2
knock-down slowed the cell cycle progression in both
cell lines and caused a low mitotic index. This precluded
adequate yield of metaphase cells for CO-FISH analysis
48 h after transfection (results not shown). As a result,
we performed the CO-FISH procedure on U2OS and
HeLa cells 72 h following BRCA2 knock-down. The
BRCA2 knock-down caused a dramatic, 9-fold reduction
( p - v a l u e=7 . 5×1 0
-12), in T-SCE frequencies in ALT
positive, U2OS cells, leading to the levels of T-SCEs
observed in non-ALT HeLa cells (Figure 3C). Similar
results were reported when FANCA and FANCD2 were
depleted in ALT positive cells [18]. The differences in T-
SCE frequencies in non-ALT HeLa cells with and
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Figure 3 BRCA2 knock-down using siRNA oligonucleotides in U2OS and HeLa cells. A. Relative quantities (RQ) of BRCA2 mRNA assessed by
quantitative real time PCR after various times following transfection with siRNA oligonucleotides specific for BRCA2. Error bars represent SD. B.
Western blot analysis of BRCA2 expression following transfection with siRNA oligonucleotides. C. Frequencies of T-SCEs in U2OS and HeLa cells
after BRCA2 depletion. T-SCE frequencies were measured 72 hrs after transfection with siRNA oligonucleotides. A minimum of 50 cells have been
analyzed in two independent experiments. Error bars represent SEM.
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Page 4 of 7without functional BRCA2 were not statistically signifi-
cantly different (p-value = 0.69). This suggests that the
transient BRCA2 knockdown is not sufficient to cause
elevated rates of T-SCEs in HeLa cells.
Interestingly, we have also observed some chromosome
fusion events after the BRCA2 knock-down in ALT posi-
tive cells (results not shown). The presence of chromo-
some fusion events is a sign of telomere dysfunction. In
order to investigate this further we analyzed frequencies
of TIFs in U2OS and HeLa cells after BRCA2 knock-
down (72 h after transfection). Since the TIF protocol
simultaneously detects DNA damage foci and telomeres
(see Material and methods) we calculated frequencies of
DNA damage foci as detected by an antibody against
gH2AX (Figure 4A). The BRCA2 depletion resulted in
increased frequencies of DNA damage in both HeLa and
U2OS cell lines (Figure 4A). As expected, U2OS cells
showed significant increase in TIF frequencies after
BRCA2 knock-down suggesting a two-fold effect of
BRCA2 on telomere maintenance in the ALT positive
cells; reduction in T-SCE frequencies and elevated fre-
quencies of dysfunctional telomeres. Increase in dysfunc-
tional telomeres after BRCA2 knockdown was also
observed in HeLa cells (Figure 4B) thus confirming
results reported in recent studies [6,7].
Taken together our results reveal two novel features of
BRCA2. First, BRCA2 suppresses recombination at telo-
meres in cells which maintain telomeres by conventional
mechanisms. Second, in cells which maintain telomeres
by ALT mechanisms BRCA2 has the opposite effect as
the frequency of an ALT marker, T-SCEs, is dramatically
reduced following the BRCA2 depletion. Given that one
of the drawbacks associated with telomerase-based can-
cer therapy is the activation of ALT [8] identification of
proteins that are essential for this mechanism is impor-
tant. It has been reported previously that the depletion of
the MRN complex [19], FANCD2 and FANCA [18] dis-
rupts the ALT pathway. Therefore, the use of BRCA2
depletion, or depletion of proteins such as MRN,
FANCD2 or FANCA, in combination with anti telomer-
ase therapeutic approaches may prevent activation of the
ALT pathway and thus make anti-telomerase mediated
tumor cell killing more effective. Furthermore, BRCA2
defective tumors may respond well to telomerase inhibi-
tion as these tumors may not be able to activate ALT.
Methods
Tissue culture
The normal human primary fibroblast cell lines,
GM08399 (purchased from Coriell Cell Repositories),
Bebu (obtained from Dr Hans Joenje, Amsterdam), Arte-
mis defective primary fibroblast cell lines FO1/240 and
CJ170 (obtained from Dr Penny Jeggo, University of Sus-
sex) and BRCA2 defective primary fibroblast cell line
EUFA423 (obtained from Dr Hans Joenje) were grown in
D-MEM medium supplemented with 10% foetal calf
serum (FCS) and antibiotics in the atmosphere of 10%
CO2. HeLa and Capan 1 cell lines were grown under the
same conditions.
Lymphoblastoid cell lines GM14622 and GM14170
established from BRCA2 heterozygote patients and a nor-
mal lymphoblastoid cell line GM00893 were purchased
from Coriell Cell Repositories and grown in RPMI-1640
Medium supplemented with 10% FCS and antibiotics. All
Chinese hamster cell lines (a gift from Dr M. Zdzienicka,
Leiden University) were grown in F10 medium supple-
mented with 10% FCS and antibiotics.
Chromosome orientation fluorescence in situ
hybridization (CO-FISH), quantitative(Q)-FISH and TIF
CO-FISH was performed as described [20]. Briefly, cells
were incubated for 24 h in the presence of Brdu and
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Figure 4 DNA damage response and telomere analysis after BRCA2 depletion.A .F r e q u e n c i e so fgH2AX foci measured 72 hrs post
transfection in U2OS and Hela. A total of 50 cells were analysed per point in two independent experiments. Error bars represent SEM B.
Frequencies of TIFs in U2OS and Hela cell lines analysed 72 hrs post transfection. A total of 50 cells were analysed per point in two independent
experiments. Error bars represent SEM. NTC (non-template control) represent scrambled siRNA.
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Page 5 of 7Brdc (3:1) (Sigma Aldrich) at a concentration of 1 × 10
-5.
Microscope slides containing chromosome preparation
were stained with Hoechst 33258 (0.5 μg/ml; Sigma
Aldrich) for 15 min at room temperature, and exposed to
365 nm UV light source (Stratelinker 1800) for 30 min.
Enzymatic digestion of the Brdu/Brdc substituted DNA
strand was performed with 3 U/ml of Exonuclease III
(Promega) in the buffer supplied by the manufacturer. In
situ hybridization was performed using the PNA oligonu-
cleotide CCCTAA labelled with FITC (PE Biosystem) as
described (10). Images of metaphase cells were captured
using a Zeiss Axioplan microscope equipped with the JAI
CCD camera and Imaging Associates software. Q-FISH
and TIF protocols were performed as described previously
[12,21]. Where the frequency of gH2AX is presented it
was extracted from the TIF results as the TIF protocol
simultaneously detects gH2AX foci and telomeres [21].
siRNA transfection and real time quantitative reverse-
transcription (qRT)-PCR
Cells were plated at a seeding density of 0.045 × 10
6 cells/
500 μl roughly equating to 40% confluency in a 24-well
plate. All siRNA transfections were done in duplicate
using ON-TARGET plus SMARTpool (Thermo Fisher
Scientific, Dharmacon Products) targeting BRCA2 gene
(NM-000059) and a non-targeting (scrambled) siRNA as a
negative control at a final concentrationof 50 nM. Trans-
fection was performed using 8 μl of jetPRIME™transfec-
tion reagent (Polyplus transfection). Total RNA was
extracted at various time points as shown in the results
section. The sequences of the human BRCA2 gene siRNA
in the SMARTpool were as recommended by the
manufacturer.
A two step qRT- PCR was performed using SYBR green
1 dye (Applied Biosystems) and expression of mRNA
quantified in real-time with an ABI prism 7900HT
sequence detection system (Applied Biosystems). The rela-
tive gene expression of BRCA2 was measured against the
endogenous GAPDH gene and calculated using ΔCt. The
sequence of BRCA2 and GAPDH primers were: forward
5’-AATGCCCCATCGATTGGTC-3’ and reverse 5’-
AGCCCCTAAACCCCACTTCAT-3’, forward 5’-GAAGG
TGAAGGTCGGAGT-3’ and reverse 5’-GAAGATGG
TGATGGGATTTC-3’ respectively.
Western blot
Western blotting has been carried out as described pre-
viously (12). Briefly, cells were lysed with 900 μlo fl y s i s
buffer (5 × sample buffer; 10% (v/v) sodium dodecyl sul-
phate, 250 mM tris pH 8.0, 50% (v/v) glycerol, 0.01%
(w/v) bromophenol blue). In addition, 50 μl of protease
inhibitor (Roche) plus 50 μl of beta-mercaptoethanol
was added and left for at least one minute followed by
mechanical shearing using a 1 ml syringe and a 23 g
needle. Samples were spun at 13,000 RPM for 5 minutes
at 4°C. Proteins were quantified usingCB-X protein
assay (G-Biosciences). Equal concentrations of 50 μg/50
μl were loaded onto a 4% until the high molecular
weight protein marker (Invitrogen) was well separated.
Following a wet blotting transfer to a polyvinylidine
fluoride (PVDF) membrane and blocking with 5% (w/v)
semi-skimmed milk (Marvel), the membrane was incu-
bated with the mouse monoclonal anti-BRCA2 antibody
(Calbiochem) and b-actin (Abcam, Cambridge, UK) in a
1:500 and 1:1000 dilution respectively at 4°C overnight
followed by incubation with secondary anti-mouse IgG-
HRP conjugated (Sigma-Aldrich) antibody at a concen-
tration of 1:5000.
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